DEERFIELD, Ill. _ Baxter International Inc. on Tuesday reported first-quarter earnings of $3.38 billion. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 29 cents per share. Four analysts surveyed by Zacks expected $2.34 billion.
Jim Cramer shares his take on caller favorite stocks at rapid speed, including this popular asset manager.
Check out the companies making headlines after the bell Tuesday: Chipotle Mexican Grill, Oracle, Pure Storage and more.
CNBC "Halftime Report" trader Pete Najarian bought shares of General Motors Thursday for his model portfolio.
An agreement would successfully end Dublin- based Shire's five-month pursuit of Bannockburn, Illinois- based Baxalta and create one of the world's leading specialists in rare diseases. Baxalta's board rejected an all-stock offer from Shire in August, saying it had significantly undervalued the company. Baxalta shares were up 4.4 percent at $39.74 in...
Activist investor Daniel Loeb has called for Dow Chemical to remove chief executive Andrew Liveris, according to The Wall Street Journal.
Dec 8- The U.S. Food and Drug Administration on Tuesday approved Baxalta Inc's Vonvendi, making it the first engineered protein-based treatment for the world's most common inherited bleeding disorder. Baxalta, spun off from Baxter International Inc earlier this year, develops biotech treatments for rare blood conditions, cancers and immune system...
Shares of medtech companies such as Edwards Lifesciences, Boston Scientific and Becton Dickinson have outperformed the broad healthcare sector, and especially pharmaceutical and biotech shares, over the past two months since U.S. presidential candidate Hillary Clinton tweeted she planned to address specialty drug "price gouging." He said he likes...
Nov 13- The U.S. Food and Drug Administration said on Friday it approved Baxalta Inc's drug for use in patients with a type of rare bleeding disorder. Baxalta, which also owns Advate, said the drug is the world's most prescribed hemophilia treatment. Baxalta, spun off from Baxter International Inc earlier this year, developed Adynovate in partnership with Nektar...
Jana Partner's Barry Rosenstein gave his latest thoughts on the market and explanations of his latest moves in a letter to clients this week.
Hedge fund Jana Partners took a long position in Microsoft, citing potential to improve operating margins and its cloud business.
Hedge fund manager Dan Loeb gave the investment rationales for two stocks and commentary on the market in a investor letter to clients.
Pete Najarian scooped up shares of JetBlue and Under Armour for his Halftime Report Portfolio on Tuesday, following a recent drop in both names.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
The 10 largest U.S. hedge funds moved out of China amid recession fears and snapped up more healthcare and pharmaceutical stocks than any other industry in Q2.
Shire, the specialty pharma company, may need to find an antidote for a poison pill before it can win shareholders in Baxalta over to its $30bn bid.
The “Mad Money” host Jim Cramer gives his take on Apple’s recent decline.
Jim Cramer reminds investors that breaking up is not always hard to do. It's easy to unlock value!
Check out the companies making headlines after the bell Wednesday: Family Dollar, Energizer & more.
Halfway through the Halftime Portfolio competition. All but two competitors are outperforming the S&P 500 so far.